MAPT and Alzheimer disease: Our analysis identified changes in the CSF of canonical AD patients, hence characterized by decrease in CSF levels of Aβ42 and an increase of tau, that were consistent with observations from several independent studies on different cohorts and using various proteomic pipelines and mass spectrometer platforms (14, 17).